Industry Insight | New Glycan Target May Advance CAR-NK Therapy for AML

April 2026 - Researchers are continuing to uncover new biological targets that could expand the potential of engineered immune cell therapies. Recently, Precision Biologics reported the identification of a novel glycan-based target that may support the development of next-generation CAR-NK cell therapies for acute myeloid leukemia (AML).

The discovery focuses on truncated core-1 O-glycans, carbohydrate structures that appear to be expressed across several AML subtypes. According to the company, these glycan markers could serve as selective recognition sites for engineered immune cells, potentially enabling therapies to more precisely identify malignant cells while minimizing damage to healthy tissue.

Photo by CDC on Unsplash

Details of the research were presented at the American Association for Cancer Research Annual Meeting 2026, where the findings highlighted the emerging role of glycan biology in immunotherapy development. Scientists involved in the work suggest that targeting tumor-associated glycans may open new opportunities for designing more specific cell therapies.

In recent years, NK-cell-based immunotherapies have gained increasing attention as an alternative or complement to CAR-T approaches. NK cells are believed to carry a lower risk of severe immune-related toxicities and may be more suitable for off-the-shelf cell therapy platforms.

Photo by Jan Kopřiva on Unsplash

However, as more CAR-NK candidates progress through research and early clinical development, the field is also confronting important manufacturing challenges. Efficient NK-cell activation, expansion, and large-scale production remain critical requirements for translating promising discoveries into viable clinical treatments.

The identification of new tumor-specific targets, combined with advances in cell engineering and manufacturing technologies, is expected to accelerate the development of next-generation NK-based therapies for hematologic malignancies such as AML.

Source: Research announcement from Precision Biologics presented at the American Association for Cancer Research Annual Meeting 2026 and reported by BioPharm International.